Join a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data.

Extracting as much information as possible from real-world datasets is essential for understanding the complete patient journey. Subtle patterns in structured and unstructured data can provide insight into disease diagnosis, progression, treatment efficacy, and overall outcomes for subcohorts and individuals. Through digital phenotyping, AI can isolate these patterns to help us better address challenges in underdiagnosis or misdiagnosis, risk and safety, gaps in care, and opportunities for new treatment.

This webinar will dive into how PhenOMTM, OM1’s AI-powered digital phenotyping platform, and real-world data can enrich and inform:

  • Subtype phenotyping
  • Enhanced diagnostic screening
  • Risk and treatment differences
  • Clinical trial enrollment
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.

Resources

Presenters

Gary Curhan, ;MD, ScD

Gary Curhan, MD, ScD

Chief Medical Officer
Research
OM1

Dr. Gary Curhan is Chief Medical Officer at OM1, a practicing nephrologist in Boston and has published widely on the epidemiology of many medical conditions including cardiovascular disease, hypertension, kidney stones, gout, and others. Dr. Curhan is a graduate of Harvard Medical School and Harvard School of Public Health.
Carl Marci, ;MD

Carl Marci, MD

Chief Psychiatrist and Managing Director
Mental Health and Neuroscience
OM1

Dr. Carl Marci is the Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1.
Stefan Weiss, ;MD, MHSc, MBA

Stefan Weiss, MD, MHSc, MBA

Managing Director of Dermatology
OM1

Dr. Stefan Weiss is the Managing Director of Dermatology at OM1. He is a board certified dermatologist, served on several national medical advisory committees and has published widely on psoriasis and atopic dermatitis. Dr. Weiss is a graduate of Yale Univ., and received his MD and MHSc in Clinical Research from the Duke Univ. School of Medicine.
Joseph Zabinski, ;PhD, MEM

Joseph Zabinski, PhD, MEM

VP, Head of Commercial Strategy & AI
OM1

Dr. Joseph Zabinski oversees design, implementation, and evolution of OM1's commercial strategy, including prioritization, GTM planning, and alignment with emergent market needs. Dr. Zabinski also serves as SME and thought leader for OM1's AI work, including applications of the PhenOM digital phenotyping platform with life science and healthcare provider partners.

Production Partner

OM1

With specialization in chronic diseases, OM1 is a leading real-world data and technology company leveraging big clinical data and AI to better understand, compare, and predict patient outcomes. We offer specialized, linked datasets; custom cohorts and registries; and an AI platform to help find undiagnosed patients and measure and predict outcomes.

VIEW PROFILE
OM1

Additional Content From OM1

Related Content